Oragenics (OGEN) Sees Strong Trading Volume

Oragenics Inc (NYSEAMERICAN:OGEN) saw unusually-strong trading volume on Friday . Approximately 24,671,928 shares were traded during trading, an increase of 868% from the previous session’s volume of 2,547,763 shares.The stock last traded at $1.35 and had previously closed at $1.01.

Oragenics (NYSEAMERICAN:OGEN) last issued its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.13).

In other news, major shareholder Family Lp Koski acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The stock was purchased at an average cost of $0.42 per share, with a total value of $42,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

TRADEMARK VIOLATION WARNING: “Oragenics (OGEN) Sees Strong Trading Volume” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/12/02/oragenics-ogen-sees-strong-trading-volume.html.

About Oragenics (NYSEAMERICAN:OGEN)

Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Recommended Story: What factors cause inflation to rise?

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit